AxoGen (NASDAQ:AXGN) released its quarterly earnings results on Sunday. The medical equipment provider reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.08, MarketWatch Earnings reports. AxoGen had a negative net margin of 22.98% and a negative return on equity of 19.83%.
NASDAQ AXGN traded up $0.54 during trading hours on Tuesday, hitting $21.73. The company’s stock had a trading volume of 24,292 shares, compared to its average volume of 249,087. The stock has a fifty day moving average of $19.02 and a 200 day moving average of $14.98. AxoGen has a twelve month low of $7.16 and a twelve month high of $21.76. The firm has a market capitalization of $882.65 million, a P/E ratio of -35.14 and a beta of 0.71. The company has a quick ratio of 6.81, a current ratio of 7.45 and a debt-to-equity ratio of 0.42.
A number of equities analysts have recently issued reports on the stock. SVB Leerink upped their target price on shares of AxoGen from $23.00 to $27.00 and gave the stock an “outperform” rating in a research report on Tuesday. Canaccord Genuity reiterated a “hold” rating and set a $21.00 target price (up from $20.00) on shares of AxoGen in a research report on Tuesday. Finally, Cantor Fitzgerald increased their price objective on shares of AxoGen from $16.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, January 12th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $23.75.
AxoGen Company Profile
AxoGen, Inc, together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
See Also: Stocks at 52 Week High
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.